CD4 and COVID-19: Strengths include thorough profiling of several features and subsets of SARS-CoV-2–specific CD4+ T cells and BMem, the relatively large size of the cohort, and cohort development beginning in spring 2020, prior to the widespread deployment of COVID-19 vaccines.